01.14.15
Plainsboro, N.J.-based Integra LifeSciences Holdings Corporation has closed the acquisition of Metasurg’s product portfolio.
The Metasurg product portfolio adds implant systems to Integra’s lower extremity product offering. It also offers the opportunity to distribute a biologic allograft derived from human placental tissue as a possible complement to Integra’s wound care product offering.
Metasurg’s revenues in 2013 were approximately $6 million, with growth in the double digits over the prior year period. The company expects minimal impact on profits in 2015 and slower growth during the transition period, before returning to double-digit growth longer term.
Metasurg was founded in 2005 in Houston, Texas, with the goal of providing foot and ankle surgeons intuitive, easy-to-use implant systems. The company has commercialized a variety of implant systems, launching five products over the last several years.
Integra provides solutions in regenerative technology, specialty surgical solutions, orthopedics and tissue technologies, and spine hardware and orthobiologics.
The Metasurg product portfolio adds implant systems to Integra’s lower extremity product offering. It also offers the opportunity to distribute a biologic allograft derived from human placental tissue as a possible complement to Integra’s wound care product offering.
Metasurg’s revenues in 2013 were approximately $6 million, with growth in the double digits over the prior year period. The company expects minimal impact on profits in 2015 and slower growth during the transition period, before returning to double-digit growth longer term.
Metasurg was founded in 2005 in Houston, Texas, with the goal of providing foot and ankle surgeons intuitive, easy-to-use implant systems. The company has commercialized a variety of implant systems, launching five products over the last several years.
Integra provides solutions in regenerative technology, specialty surgical solutions, orthopedics and tissue technologies, and spine hardware and orthobiologics.